Second-line treatment after disease progression following first-line chemotherapy with modified FOLFIRINOX in advanced pancreatic cancer patients

被引：1
|
作者：
Vivaldi, C. [1 ]
Vasile, E. [1 ]
Fornaro, L. [1 ]
Caparello, C. [1 ]
Musettini, G. [1 ]
Pasquini, G. [1 ]
Lencioni, M. [2 ]
Ricci, S. [2 ]
Falcone, A. [1 ]
机构：
[1] Azienda Osped Univ Pisana, UO Oncol Med Univ 2, Pisa, Italy
[2] Azienda Osped Univ Pisana, UO Oncol Med Osped 1, Pisa, Italy
来源：
EUROPEAN JOURNAL OF CANCER | 2015年 / 51卷
关键词：
D O I：
10.1016/S0959-8049(16)31278-3
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2362
引用
收藏
页码：S456 / S457
页数：2
相关论文
共 50 条
  • [41] First-Line Treatment for Advanced Pancreatic Cancer
    Oberstein, Paul E.
    Saif, Muhammad Wasif
    JOURNAL OF THE PANCREAS, 2011, 12 (02): : 96 - 100
  • [42] Oral chemotherapy for second-line treatment in patients with gemcitabine-refractory advanced pancreatic cancer
    Se Jun Park
    Hyunho Kim
    Kabsoo Shin
    Myung Ah Lee
    Tae Ho Hong
    World Journal of Gastrointestinal Oncology, 2019, (11) : 1021 - 1030
  • [43] Beneficial trends of second-line chemotherapy in advanced pancreatic cancer
    Silva, Milton Jose B.
    Maia, Joyce Maria L.
    Ribeiro, Adriana Regina G.
    Chinen, Ludmilla T. D.
    Paiva, Tadeu Ferreira, Jr.
    Padua, Fernando Vidigal
    Ismael Pinto, Flavio Augusto
    Santos, Elizabeth Santana
    Mello, Celso Lopes
    Campanha, Daniel
    Rodrigues Pereira, Augusto Akikubo
    Fanelli, Marcello Ferretti
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [44] Oral chemotherapy for second-line treatment in patients with gemcitabine-refractory advanced pancreatic cancer
    Park, Se Jun
    Kim, Hyunho
    Shin, Kabsoo
    Lee, Myung Ah
    Hong, Tae Ho
    WORLD JOURNAL OF GASTROINTESTINAL ONCOLOGY, 2019, 11 (11) : 1021 - 1030
  • [45] The First-Line Treatment for Advanced Pancreatic Cancer
    Merl, Man Yee
    Li, Jia
    Saif, Muhammad Wasif
    JOURNAL OF THE PANCREAS, 2010, 11 (02): : 148 - 150
  • [46] Efficacy of second-line nivolumab after early time to progression on first-line cytotoxic chemotherapy in patients with advanced non-small cell lung cancer (NSCLC)
    Ota, T.
    Kirita, K.
    Udagawa, H.
    Umemura, S.
    Matsumoto, S.
    Yoh, K.
    Niho, S.
    Goto, K.
    ANNALS OF ONCOLOGY, 2018, 29
  • [47] Treatment Outcomes and Prognostic Factors of Gemcitabine Plus Nab-Paclitaxel as Second-Line Chemotherapy after Modified FOLFIRINOX in Unresectable Pancreatic Cancer
    Mie, Takafumi
    Sasaki, Takashi
    Takeda, Tsuyoshi
    Okamoto, Takeshi
    Hamada, Tsuyoshi
    Ishitsuka, Takahiro
    Yamada, Manabu
    Nakagawa, Hiroki
    Furukawa, Takaaki
    Kasuga, Akiyoshi
    Matsuyama, Masato
    Ozaka, Masato
    Sasahira, Naoki
    CANCERS, 2023, 15 (02)
  • [48] Feasibility study of FOLFIRINOX as first-line chemotherapy for metastatic pancreatic cancer (KOBE FOLFIRINOX study)
    Hatachi, Yukimasa
    Satake, Hironaga
    Kotake, Takeshi
    Ogata, Takatsugu
    Okita, Yoshihiro
    Yasui, Hisateru
    Tsuji, Akihito
    ANNALS OF ONCOLOGY, 2017, 28
  • [49] Impact of peripheral neuropathy induced by platinum in first-line chemotherapy on second-line chemotherapy with paclitaxel for advanced gastric cancer
    Otsuka, Ryo
    Iwasa, Satoru
    Yanai, Takako
    Hirano, Hidekazu
    Shoji, Hirokazu
    Honma, Yoshitaka
    Okita, Natsuko
    Takashima, Atsuo
    Kato, Ken
    Hashimoto, Hironobu
    Sekiguchi, Masatoshi
    Makino, Yoshinori
    Boku, Narikazu
    Yamaguchi, Masakazu
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2020, 25 (04) : 595 - 601
  • [50] Impact of peripheral neuropathy induced by platinum in first-line chemotherapy on second-line chemotherapy with paclitaxel for advanced gastric cancer
    Ryo Otsuka
    Satoru Iwasa
    Takako Yanai
    Hidekazu Hirano
    Hirokazu Shoji
    Yoshitaka Honma
    Natsuko Okita
    Atsuo Takashima
    Ken Kato
    Hironobu Hashimoto
    Masatoshi Sekiguchi
    Yoshinori Makino
    Narikazu Boku
    Masakazu Yamaguchi
    International Journal of Clinical Oncology, 2020, 25 : 595 - 601
12345